Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients
| Autor: | Laurent Perard, O Lidove, P. Le Hoang, Philip Bielefeld, Marc Lambert, Bertrand Wechsler, M. Resche Rigon, Eric Hachulla, Alice Sanna, F. Cohen, Patrice Cacoub, Jl Pasquali, Yoland Schoindre, Jean Sibilia, Isabelle Marie, Olivier Fain, Damien Sène, Bahram Bodaghi, Carlo Salvarani, H. Vallet, Sophie Rivière, J.B. Fraison, Guillaume Moulis, Olga Addimanda, Xavier Mariette, Thomas Papo, Pascal Sève, D. Saadoun, Alban Deroux, L. Bouillet |
|---|---|
| Přispěvatelé: | Vallet, H., Riviere, S., Sanna, A., Deroux, A., Moulis, G., Addimanda, Olga, Salvarani, C., Lambert, M., Bielefeld, P., Seve, P., Sibilia, J., Pasquali, Jl, Fraison, Jb, Marie, I., Perard, L., Bouillet, L., Cohen, F., Sene, D., Schoindre, Y., Lidove, O., Le Hoang, P., Hachulla, E., Fain, O., Mariette, X., Papo, T., Wechsler, B., Bodaghi, B., Rigon, M. Resche, Cacoub, P., Saadoun, D. |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Vasculiti medicine.medical_specialty Efficacy Immunology Mucocutaneous zone Alpha (ethology) Disease Behcet's disease Severity of Illness Index Gastroenterology Anti-TNF Immunosuppressive Agent Immunologic Factor Refractory Recurrence Retrospective Studie Internal medicine Adalimumab medicine Humans Immunologic Factors Immunology and Allergy Retrospective Studies Behçet's disease Safety Vasculitis Tumor Necrosis Factor-alpha business.industry Behcet Syndrome Medicine (all) Incidence (epidemiology) Antibodies Monoclonal medicine.disease Infliximab Surgery Treatment Outcome Retreatment Female business Immunosuppressive Agents Human medicine.drug |
| Zdroj: | Journal of Autoimmunity. 62:67-74 |
| ISSN: | 0896-8411 |
| Popis: | Objective: To report the efficacy and safety of anti-TNF agents in patients with severe and/or refractory manifestations of Behçet's disease (BD). Methods: We performed a multicenter study of main characteristics and outcomes of anti-TNF alpha treatments [mainly infliximab (62%), and adalimumab (30%)] in 124 BD patients [48% of men; median age of 33.5 (28-40) years]. Results: Overall response (i.e. complete and partial) rate was 90.4%. Clinical responses were observed in 96.3%, 88%, 70%, 77.8%, 92.3% and 66.7% of patients with severe and/or refractory ocular, mucocutaneous, joint, gastro-intestinal manifestations, central nervous system manifestations and cardiovascular manifestations, respectively. No significant difference was found with respect to the efficacy of anti-TNF used as monotherapy or in association with an immunosuppressive agent. The incidence of BD flares/patient/year was significantly lower during anti-TNF treatment (0.2±0.5 vs 1.7±2.4 before the use of anti-TNF, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect